Riogin developed a technology platform that overcomes many of the problems connected to peptide therapeutics, which represents a growing portion of the market opportunity for big biopharma. Current peptide drugs suffer from issues related to short half-lives, inconvenient frequency of dosing and administration, and undesirable side-effects. Riogin's novel double-binding approach solves many of these problems and has the potential to make existing and future peptide drugs better and safer.
